Robust induction of DARPP32-expressing GABAergic striatal neurons from human pluripotent stem cells by Fjodorova, Marija & Li, Meng
1 
Note to copy editor: Standard Methods Chapter format 
 
 
 
Robust induction of DARPP32 expressing GABAergic striatal neurons from 
human pluripotent stem cells 
 
 
Marija Fjodorova1 and Meng Li 
Neuroscience and Mental Health Research Institute, School of Bioscience, Cardiff 
University, Cardiff, CF24 4HQ, UK 
Corresponding Author: marija.fedorova@gmail.com (M. Fjodorova) 
 
Running Head: Derivation of MSNs from hPSCs 
 
 
2 
Abstract 
Efficient generation of disease relevant neuronal subtypes from human pluripotent 
stem cells (PSCs) is fundamental for realising their promise in disease modelling, 
pharmaceutical drug screening and cell therapy. Here we describe a step-by-step 
protocol for directing the differentiation of human embryonic and induced PSCs 
(hESCs and hiPSCs, respectively) towards medium spiny neurons, the type of cells 
that are preferentially lost in Huntington’s disease patients. This method is based on 
a novel concept of Activin A-dependent induction of the lateral ganglionic/striatal fate 
using a simple monolayer culture paradigm under chemically defined conditions. 
Transplantable medium spiny neural progenitors amenable for cryopreservation are 
produced in less than 20 days, which differentiate and mature into a high yield of 
dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP32) expressing 
gamma-aminobutyric acid (GABA)-ergic neurons in vitro and in the adult rat brain 
after transplantation. This method has been validated in multiple hESC and hiPSC 
lines, and is independent of the regime for PSC maintenance. 
 
Key words: Activin, DARPP32, lateral ganglionic eminence, medium spiny neuron, 
pluripotent stem cell, neural differentiation, Huntington’s disease, striatum, 
transplantation. 
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1 Introduction 
Preferential loss of the -amino butyric acid (GABA)-ergic medium-sized spiny 
neurons (MSNs) in the striatum is the primary pathology of Huntington’s disease 
(HD) (1). Whilst it is known that MSN degeneration is caused by an extended CAG-
repeat mutation in the Huntingtin (HTT) gene, the cellular and molecular mechanism 
by which mutant HTT protein triggers striatal cell death remains largely unknown. 
Consequently, there is currently no cure for HD. Human MSNs generated in vitro 
from healthy pluripotent stem cells (PSCs) offer great promise for developing cell-
based therapy for treating HD, while those derived from patient cells or engineered 
to carry the mutant HTT gene would serve as a useful platform for understanding the 
aetiology of HD and drug discovery therein. 
 
1.1 Generation of striatal neurons from pluripotent stem cells 
We have recently reported a highly reliable generation of MSNs from human 
embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) (2). The 
method is a simple monolayer differentiation procedure using a single chemically 
defined basal medium formula throughout. Unique to this protocol is the application 
of Transforming Growth Factor-β (TGF-β) family protein Activin A (referred to 
hereafter as activin) during a defined window of neural conversion. Previous studies 
showed the presence of activin subunits, receptors and their transcriptional effectors, 
the Smad proteins, in the developing subpallium (3,4), suggesting potential 
regulation of striatal development by TGF-β family signalling. In line with these 
findings, we subjected hPSC-derived forebrain progenitors to activin treatment to 
induce an MSN fate specification (2). This resulted in a rapid upregulation of CTIP2 
(also known as BCL11B), a transcription factor required for MSN development in 
vivo and the only transcription factor reported capable of directly programming skin 
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fibroblasts into functional MSNs (5,6). We also demonstrated that neural progenitors 
obtained using this protocol are committed to a striatal fate that exhibit 
characteristics of the lateral ganglionic eminence (LGE) such as expression of 
specific markers including NOLZ1 and FOXP2. Furthermore, induction of these 
striatal transcripts by activin can be completely blocked by a specific activin/SMAD 
inhibitor, SB431542, suggesting that the specification of an LGE-derived MSN fate in 
this system requires the TGF-β family signalling via activation of the SMAD2/3 
pathway. 
Sonic hedgehog (SHH)-based morphogen signalling has been exploited previously 
for generating dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa 
(DARPP32) expressing MSNs from hESCs (7-9). Resulting MSN progenitors 
expressed pan-GE markers FOXG1, OTX2 and GSX2. However, LGE-specific 
transcription factor CTIP2 was unaffected and other LGE markers were not analysed 
at progenitor stage. In contrast, our studies on multiple hPSC lines support the 
notion that activin preferentially induces LGE/MSN characteristics whilst SHH elicits 
a generic ventralising effect with no apparent activity on LGE-specific gene 
expression. Technically, the current method implements a simple monolayer 
differentiation paradigm without the need for embryoid body or aggregate formation 
used in earlier studies, which in our hands tend to generate more heterogeneity and 
is less reproducible. Moreover, compared to the others, our method takes a shorter 
time to produce LGE progenitors, the likely target for a cell therapy product, and 
postmitotic DARPP32+ MSNs. 
For most of the hPSC lines tested, our method requires no passaging for obtaining 
neural progenitors committed to a striatal fate that exhibit characteristics of the LGE; 
and hence just one passaging step is necessary to facilitate terminal differentiation of 
the neural progenitors towards MSNs and their maturation and survival. So far, the 
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protocol has been shown to be effective in five hESC lines and two hiPSC lines, 
including the research stock of good manufacturing practice (GMP) grade RC9 and 
RC17 hESCs (http://www.nibsc.org). Moreover, the protocol performs well 
independently of the culture conditions of hPSC lines, i.e. whether the cells were 
routinely maintained on feeders or in feeder-free conditions, the supporting matrix 
the cells were grown on, the types of culture media used for maintaining self-renewal 
or dissociation methods implemented to passage hPSCs. Additionally, LGE 
progenitors generated are sufficiently robust to survive cryopreservation for future 
experiments. Once thawed, they readily undergo terminal differentiation into MSNs in 
vitro or can be transplanted into the lesioned animal striatum.    
 
1.2 Experimental Design 
Maintenance of hPSC cultures in feeder-free conditions. This protocol is written with 
feeder-free hPSC (ESC or iPSC) cultures as the starting material, although it also 
applies to hPSCs maintained on feeders. For the latter, an extra step of plating 
before seeding for differentiation is required to remove the feeder cells (see Note 1). 
However, for a better and reliable yield of MSNs, it is advisable to wean the hPSC 
lines off feeders. 
Monolayer differentiation of hPSC cultures towards LGE progenitors. An overview of 
the experimental procedure is given in Figure 1a. Derivation of LGE progenitors 
from hPSC cultures is a technically simple procedure that consists of two main 
stages. Firstly, pluripotent cells are converted into forebrain progenitors with a 
cocktail of SMAD inhibitors and then patterned towards an LGE fate with activin. 
Refer to Figure 1b for characteristic morphology of intermediate progenitors at each 
stage of the protocol.  
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Insert Figure 1 about here 
 
The first stage of differentiation entails efficient neural conversion of hPSCs within 
nine days under adherent culture conditions using a modified dual-SMAD inhibition 
protocol (10,11). In contrast to Chambers et al. who gradually replace media 
supplemented with knockout serum replacement with that of N2 during the early 
phase of neural fate conversion, we begin the neural induction with N2B27 medium 
and use this single medium formula throughout the protocol (see Cell Culture 
Reagents and Setup for a detailed medium composition). A relatively high cell 
density at the onset of differentiation is optimal for efficient induction of forebrain 
progenitor fate. Crucially, we use retinol-free B27 for the first 20 days to reduce 
caudalisation and maximise subsequent LGE patterning.  
Induction of the LGE fate in FOXG1 expressing forebrain progenitors is achieved by 
using activin as the exogenous patterning factor. This step generally starts from day 
9, or day 10 for cultures that need a passage step at day 9, by replacing the SMAD 
inhibitors with activin. Refer to Figure 1b for characteristic morphology of 
differentiating LGE progenitors. Rosettes can be visible in cultures re-plated at day 9 
but these structures may not be apparent in cultures without this extra passage. It is 
advisable to include a no activin control in the experimental design. These neural 
progenitors will adopt a dorsal telencephalic fate, demonstrated by their expression 
of PAX6 and DMRT5, and later give rise to cortical pyramidal neurons.  
LGE progenitors derived from this stage of the protocol may be analysed by 
immunofluorescence (IF) staining and qRT-PCR, re-plated and terminally 
differentiated into MSNs (Figure 2), or transplanted into the lesioned animal striatum 
for further analyses. They also have the advantage over earlier progenitors of being 
robust enough to be cryopreserved for future experiments. Frozen stocks of LGE 
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neural progenitors remain viable long-term when stored in liquid nitrogen. Upon 
thawing, LGE progenitors can be terminally differentiated into MSNs in vitro or 
transplanted into an animal model of HD (Figure 3). 
 
Insert Figures 2 and 3 about here 
 
2 Materials 
2.1 Cell Culture Reagents and Setup 
1. hPSC culture medium: mTeSRTM1, TeSRTM-E8TM Kit for hESC/hiPSC 
Maintenance (E8 medium) or StemPro® hESC SFM Kit. 
2. Cell culture substrates: Matrigel® Matrix hESC-qualified, CELLstartTM CTSTM 
Substrate (see Note 2), Matrigel® Growth Factor Reduced Basement Membrane 
Matrix (GFR Matrigel), Human Plasma Fibronectin Purified Protein (Fibronectin), 
Laminin, and Poly-D-lysine hydrobromide (PDL). 
3. Cell dissociation reagents: EDTA 0.02% solution for cell culture applications and 
Accutase. 
4. Dulbecco’s phosphate-buffered saline (DPBS) without calcium and magnesium 
(DPBS -Ca-Mg) for cell culture applications 
5. N2B27 complete differentiation medium (150 mL): 100 mL of DMEM/F-12 
medium, 50 mL of Neurobasal medium, 1.5 mL of 200 mM L-Glutamine, 1.5 mL 
of 10,000 U/mL Penicillin/Streptomycin, 1 mL of 100X N-2 supplement 
(supplemented 1:10 with 7.5% Bovine Serum Albumin), 1 mL of 50X B-27 
supplement (with/without vitamin A), and 150 µL of 50 mM 2-Mercaptoethanol 
solution [CAUTION: 2-Mercaptoethanol is toxic if inhaled, ingested or spilled on 
skin. Wear gloves and lab coat and handle it with care under a chemical 
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cabinet.]. Mix N2B27 medium throughout and store at 4 °C. For best effect, it is 
advisable to use the complete N2B27 medium within a month. 
6. Neural induction medium A: complete N2B27 medium without vitamin A, 100nM 
LDN-193189, 200 nM Dorsomorphin dihydrochloride, 10 µM SB 431542. 
Complete medium with factors can be kept at 4 °C for several days but use fresh 
medium if there is any noticeable decrease in cell growth rate.  
7. Neural induction medium B: complete N2B27 medium without vitamin A, 100nM 
LDN-193189, 200 nM Dorsomorphin dihydrochloride. 
8. LGE patterning medium: complete N2B27 medium minus vitamin A, 25 ng/mL 
recombinant human Activin A. 
9. Terminal differentiation medium: complete N2B27 medium with vitamin A, 10 
ng/mL recombinant human BDNF, 10 ng/mL recombinant human GDNF. 
10. Y-27632 RHO/ROCK pathway inhibitor (ROCK inhibitor) 
11. Cell freezing medium: Cell culture medium supplemented with 10% (vol/vol) 
dimethyl sulfoxide (DMSO) or CryoStor® CS10 Cryopreservation Medium 
(STEMCELL Technologies). 
 
2.2 IF Staining 
1. PBS buffer: deionized water, 0.01 M phosphate buffer, 0.0027 M potassium 
chloride, 0.137 M sodium chloride, pH 7.4 at 25 °C. 
2. Cell fixation solution: 3.7% (wt/vol) paraformaldehyde solution in PBS 
[CAUTION: Paraformaldehyde is extremely toxic and must be handled under a 
chemical cabinet. Gloves and lab coat should be worn to avoid contact with 
skin.] 
3. 0.3% PBST buffer for immunofluorescence staining: 1L PBS, 3 mL Triton X-100. 
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4. Blocking buffer for IF staining: 1% (wt/vol) BSA and 3% (vol/vol) donkey serum 
solution in PBST. 
5. Hoechst 33258, 10 mg/mL solution in water 
6. Dako Fluorescent Mounting Medium 
7. A summary of antibodies we routinely use is presented in Table 1 
 
Insert Table 1 about here 
 
2.3 RNA extraction, RT-PCR and qRT-PCR 
1. TRI Reagent [CAUTION: TRI Reagent is extremely toxic and must be handled 
under a chemical cabinet. Gloves and lab coat should be worn to avoid contact 
with skin.] 
2. Chloroform [CAUTION: Chloroform is toxic if inhaled, ingested or spilled on skin. 
Wear gloves and lab coat and handle it with care under a chemical cabinet.] 
3. Ethanol [CAUTION: Ethanol is toxic if inhaled, ingested or spilled on skin. Wear 
gloves and lab coat and handle it with care under a chemical cabinet.] 
4. DEPC-treated water 
5. SuperScript III First-Strand Synthesis System (Life Technologies)  
6. iQ™ SYBR® Green Supermix (Bio-Rad) 
7. The sequence information for validated PCR primers is summarised in Table 2 
 
Insert Table 2 about here 
 
2.4 Equipment 
1. 15, 30 & 50 mL conical centrifuge tubes 
2. 10, 20, 200 & 1000 µl sterile pipette tips 
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3. 2, 5, 10, 25 & 50 mL sterile serological pipettes 
4. Electronic pipettor  
5. 6-, 12-, 24-well Nunc™ Cell-Culture Treated Multidishes 
6. 1.8 mL Sterile Cryogenic Vials 
7. 250 mL Solution Bottle 
8. ⊘ 13 mm Glass coverslips 
9. Glass Microscope Slides 
10. 1.5 mL RNase-free Screw-Cap Microcentrifuge Tubes  
11. 96-well PCR plate 
12. Mr. FrostyTM Freezing Container 
13. Laminar Flow Biosafety Cabinet 
14. Humidified 5% CO2 37°C Incubator 
15. Waterbath 
16. Centrifuge 5810 R 
17. Phase-contrast Inverted Microscope 
18. Plate vortexer 
19. Rocker 
20. Fluorescence Microscope 
21. Centrifuge 5424 R 
22. BioSpectrometer basic 
23. Thermocycler  
24. Chromo4 System (Bio-Rad) 
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3 Methods 
3.1 Preparation of hPSC Culture for Neuronal Differentiation in Feeder-free 
Conditions  
1. Every lot of Matrigel® Matrix hESC-qualified matrix (Matrigel) can have a slightly 
different concentration of proteins, thus the suggested dilution ratio will vary from 
batch to batch and will be indicated on the datasheet. Dilute Matrigel in 
DMEM/F-12 as suggested and coat 6-well culture plates at the volume of 1 
mL/well. Gently shake the plate to cover all the surface area with the coating 
solution and transfer to a humidified 5% CO2 37 °C incubator for at least 1 hour. 
When this is ready, transfer Matrigel to new wells (can be re-used once) and 
wash the coated wells once with DPBS -Ca-Mg before plating cells. 
2. Thaw hPSCs and plate in E8 medium (see Note 3) at a density of 0.75 - 1 x 106 
cells per well of a 6-well plate for a successful outcome. 
3. Expand if necessary and grow hPSC cultures to 70 – 80% confluence prior to 
seeding cells for a differentiation. Typically, two wells of a 6-well plate of hPSCs 
are required for seeding one full 6-well or 12-well plate for differentiation at a 
density of 70,000 – 100,000 cells/cm2 (see Note 4).  
4. On the day of seeding cells for a differentiation, pre-coat culture containers with 
GFR Matrigel (see Note 5). For a thin coating method dilute 1:15 GFR Matrigel 
in ice cold DMEM/F12, mix throughout and add 0.5 mL/well into each well of a 
12-well plate or 1 mL/well into each well of a 6-well plate. Coat culture vessels 
on the day of use in a humidified 5% CO2 37 °C incubator for 1 – 1.5 hours. 
Aspirate unbound material from coated wells and rinse gently once using DPBS -
Ca-Mg. Plates are now ready to use. Use 6-well plates for large-scale 
experiments (e.g. transplantation or banking of LGE progenitors) and 12-well 
plates for small-scale experiments and qRT-PCR and IF staining analyses. 
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5. Aspirate old culture medium from the cells to be used and then gently wash wells 
with 2 mL of DPBS -Ca-Mg. 
6. Remove DPBS -Ca-Mg from culture vessels and add 1 mL of Gentle Cell 
Dissociation Reagent or EDTA 0.02% solution to each well and incubate at 37 
°C 5% CO2 for 2 – 5 minutes. If using EDTA, treat cells for 2 minutes at 37°C 5% 
CO2. Incubation time may vary among different cell lines and depending on the 
coating matrix in use. Therefore, inspect the plates under a microscope and stop 
the reaction when edges of the colonies start to pull away from the plate and 
white gaps appear between cells. 
7. Aspirate the dissociation medium leaving the cells attached to the bottom of the 
well and immediately add 3 mL of culture medium to the cells. Some detachment 
of cells upon addition of culture medium is normal at this stage. 
8. Using a 10 mL serological pipette, very gently scratch the bottom of the well to 
dislodge cells in small clumps (50 – 100 μm). Not all cells will detach, this is 
normal. 
9. Collect most of the cells from the well and transfer them to a 30 mL universal 
tube. Dilute collected cell suspension with hPSC culture medium to achieve a 
seeding density of 70,000 – 100,000 cells/cm2. Gently dissociate cells into small 
clusters by carefully pipetting 2 – 3 times with a serological pipette (see Note 6).  
10. Seed cells for a differentiation into pre-coated culture vessels (see Note 1). The 
final volume of medium should be 1 mL/well for 12-well plate or 3 mL/well for 6-
well plate. Transfer culture containers to the 37 °C 5% CO2 incubator and be 
sure to gently move the plates in several quick, short, side-to-side and back-and-
forth motions to obtain even distribution of cells. 
11. Inspect the hPSC cultures the next morning under a microscope.  Cells should 
have attached as small undifferentiated colonies in a monolayer evenly 
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distributed across the wells (see Note 7). Slightly swirl the plate immediately 
before feeding hPSCs to collect dead cells and debris in the middle of culture 
vessels. Aspirate old medium with dead cells and replace it with 1.5 mL/well for 
12-well plates or 3 mL/well for 6-well plates of pre-warmed fresh hPSC culture 
medium. 
12.  Incubate the plates at 37 °C with 5% CO2. Feed cells daily until cultures reach 
80 – 90% confluence, at which point move to the next stage. Aim to start 
differentiation 2 – 3 days after seeding cells. If it takes cultures longer to grow 80 
– 90% confluent, seed higher cell concentrations. 
 
3.2 Monolayer Differentiation of hPSCs to Forebrain Progenitors 
1. Once hPSC cultures grow to 80 – 90% confluent, aspirate all hPSC culture 
medium and gently wash cells once with DPBS -Ca-Mg. Do not wait until hPSC 
cultures grow 100% confluent before starting a differentiation as this increases 
cell death and leads to poor neural induction. 
2. Remove DPBS -Ca-Mg from culture vessels and add pre-warmed neural 
induction medium A. The final volume should be 3 mL/well for a 6-well plate or 
1.5 mL/well for a 12-well plate. This day is designated as Day 0 (D0) of 
differentiation. Incubate the plates in the humidified 37 °C 5% CO2 incubator. 
Depending on a cell proliferation rate, either daily or every other day swirl the 
plate gently immediately before feeding to collect dead cells and debris in the 
middle of the well. Replace ⅔ of old medium with fresh pre-warmed medium. 
Inspect differentiating cultures under a microscope every day and observe 
changes in cell morphology towards a round shape, reduction in size and 
nucleus-to-cytoplasm ratio, all of which are characteristic features of cells exiting 
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a pluripotent stage and committing to a telencephalic fate as shown in Figure 
1b. Keep differentiating cells in neural induction medium A until D5.  
3. On D5 of differentiation, feed cultures with neural induction medium B. Keep 
cells in neural induction medium B until D9. Feed the cultures either daily or 
every other day depending on the density and growth rate of differentiating cells. 
4. D9 of differentiation signifies the end of neural induction phase. Refer to Figure 
1b for representative cellular morphology of cultures committed to the 
neuroectoderm. To characterise forebrain progenitors at this stage, cells can be 
fixed for IF staining and lysed to extract RNA for qRT-PCR analysis. If 
differentiating cells require passaging onto Fibronectin-coated plates at this 
stage follow steps in 3.3, alternatively proceed to 3.4. 
 
3.3 Passage of Forebrain Progenitors onto Fibronectin-coated Culture Vessels 
1. For a successful outcome, some cell lines (e.g. H7, H9) differentiating on GFR 
Matrigel require passaging once they start forming multi-layered cultures during 
D8-12 of differentiation (see Note 8). Otherwise, forebrain precursors become 
stressed, start to detach from the matrix and fail to differentiate into LGE 
progenitors. Also, with some batches of CELLstart, neuroectodermal-like cells 
should be passaged at this stage or they will detach from the matrix and die. 
2. On the day of passage, coat culture vessels with Fibronectin solution (15 µg/mL 
in DPBS -Ca-Mg) for at least 1 hour in a humidified 5% CO2 37 °C incubator. 
Use 6-well plates for large-scale experiments (e.g. transplantation or banking of 
LGE progenitors) and 12-well plates for small-scale experiments and qRT-PCR 
and IF staining analyses. 
3. Depending on what day of differentiation forebrain progenitors are being 
passaged on, prepare the volume of neural induction medium B or LGE 
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patterning medium supplemented with 10 µM ROCK inhibitor enough to passage 
cells at a 2:3 ratio based on the area of culture containers plus extra 2 – 3 mL 
and pre-warm to room temperature. The final volume for seeding forebrain 
progenitors should be 2 mL/well for 6-well plates or 1 mL/well for 12-well plates. 
4. Discard ⅔ of old medium from each well and replace it with fresh medium 
supplemented with ROCK inhibitor from the previous step. Incubate cells for at 
least 1 hour at 37 °C 5% CO2. 
5. Following ROCK inhibitor treatment, collect ⅔ of medium from each well into a 
50 mL centrifuge tube. Aspirate the remaining medium and gently wash cultures 
once with DPBS -Ca-Mg.  
6. Discard DPBS -Ca-Mg and add 1 mL/well for 6-well plates or 0.5 mL/well for 12-
well plates of EDTA 0.02% solution. Incubate cells in EDTA for 1 – 2 minutes at 
37 °C 5% CO2 until small gaps between cells become visible under a light 
microscope (see Note 9). Aspirate EDTA and, without washing cells, add 
previously collected medium back into each well. Using a 10 mL serological 
pipette, very gently scratch the bottom of the well to dislodge cells in large 
clumps (300 – 600 μm). Not all cells will detach, this is normal. 
7. Collect most of the cells from all wells within the same experimental group and 
transfer them to a 50 mL centrifuge tube. Dilute the cell suspension with fresh 
medium to the required volume as determined in Step 3. Aspirate Fibronectin 
solution from coated culture vessels and discard. It is not necessary to rinse 
coated wells before seeding cells. Using a serological pipette, very gently mix 
the cell suspension by carefully pipetting 1 – 2 times and seed cells into pre-
coated wells in 2 mL/well for 6-well plates or 1 mL/well for 12-well plates.  
8. Transfer the plates to a humidified 37 °C incubator with 5% CO2 and ensure cells 
are distributed evenly across wells by gently moving the plates in several quick, 
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short, side-to-side and back-and-forth motions. On the next day, proceed to the 
next stage. 
 
3.4 Patterning of Forebrain Progenitors towards the LGE Fate 
1. On D9 of differentiation, prepare fresh LGE patterning medium to feed cells with 
1.5 mL/well for 12-well plates or 3 mL/well for 6-well plates and pre-warm to 
room temperature. It is important to have culture vessels with forebrain 
progenitors that are not being treated with activin to use as a negative control in 
future analyses. Keep control cultures in N2B27 medium minus vitamin A. 
2. Remove most of old medium from each well leaving just a thin film of liquid to 
cover cells and add pre-warmed LGE patterning medium. Incubate plates at 37 
°C 5% CO2. 
3. Inspect the cells daily and replace ⅔ of the LGE patterning medium every other 
day with fresh pre-warmed medium until D20. Refer to Figure 1b for 
representative cellular morphology of neuronal progenitors at this stage. 
4. D20-22 of differentiation signify the end of the LGE patterning phase. LGE 
progenitors, the end product of this stage of the protocol, can be characterised 
by IF staining and qRT-PCR, re-plated onto PDL/Laminin and terminally 
differentiated into MSNs in vitro, transplanted into an animal model of HD for 
further analysis or cryopreserved for future experiments. 
 
3.5 Terminal Differentiation of LGE Progenitors into MSNs 
1. For the terminal differentiation into MSNs in vitro, passage LGE progenitors on 
D20-22 of differentiation at a split ratio of 1:1 – 1:5 based on the area of culture 
vessels. One day before the passage, start preparing the required number of 
PDL/Laminin-coated culture vessels. Use 12-well plates for qRT-PCR analysis 
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and glass coverslips in 24-well plates for IF staining. Dilute PDL in DPBS -Ca-Mg 
to 10 µg/mL concentration and apply coating solution at a final volume of 0.25 
mL for 24-well plates or 0.5 mL for 12-well plates. Coat tissue culture vessels 
with PDL in a humidified 5% CO2 37 °C incubator for at least 2 hours. After this, 
discard PDL coating solution and wash coated culture containers with DPBS -
Ca-Mg. Dilute Laminin in DPBS -Ca-Mg to 10 µg/mL concentration and apply 
coating solution overnight in a humidified 5% CO2 37 °C incubator. When this is 
done aspirate Laminin solution from culture vessels and discard. It is not 
necessary to rinse coated wells before seeding cells. 
2. Remove the medium from cultures and gently wash cells once with DPBS -Ca-
Mg. Discard DPBS -Ca-Mg and incubate cells in EDTA 0.02% solution for 2–3 
minutes at 37 °C 5% CO2.  
3. Aspirate EDTA and, without washing cells, add 2 mL/well for 6-well plates or 1 
mL/well for 12-well plates of pre-warmed LGE patterning medium. Using a 1000 
µL pipette tip, very gently scratch the bottom of the well to dislodge cells. LGE 
progenitors are quite robust and can be collected in very small clumps (up to 
quasi-single cell suspension) at this stage. 
4. Collect most of the cells from all wells within the same experimental group and 
transfer them to a 50 mL centrifuge tube. Dilute the cell suspension in the 
required volume of pre-warmed LGE patterning medium to seed cells in 1 
mL/well for 12- and 24-well plates. Seed LGE progenitors into the culture 
container and transfer the plate to a humidified 5% CO2 37 °C incubator and 
ensure cells are distributed evenly across wells by gently moving the plate in 
several quick, short, side-to-side and back-and-forth motions. 
5. On the following day, pre-warm enough terminal differentiation medium to feed 
cells with 1.5 mL/well for 12-well plates or 1 mL/well for 24-well plates. Gently 
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swirl the plate immediately before feeding to collect dead cells and debris in the 
middle of the well. Aspirate most of the old medium from each well leaving just a 
thin film of liquid to cover cells, add fresh pre-warmed medium and return the 
plates to the humidified 5% CO2 37 °C incubator. Every other day or as needed, 
feed cells with terminal differentiation medium until the end of the experiment by 
replacing ⅔ of old culture medium per well with pre-warmed fresh medium. 
Neurons can be maintained in culture for over 3 months, although we tend to do 
most of our initial IF staining (Figures 2 and 3) and qRT-PCR analyses on D35-
40 of differentiation. 
 
3.6 Characterisation of cells in vitro 
The following options describe processing of cell cultures to produce fixed cells or 
RNA, as required for further analysis. To fix cells and perform IF staining, follow 
option A. To extract RNA from cells and perform qRT-PCR, follow option B. 
 
3.6.1 Fixation of cultures and IF staining 
1. Wash cells gently once with DPBS -Ca-Mg and discard the liquid. 
2. Add 250 µL/cm2 of cold 3.7% (wt/vol) PFA solution per well and incubate 
cells at 4 °C for 15 minutes. 
3. Remove PFA solution and place it in a hazardous waste container 
[CAUTION: Paraformaldehyde is extremely toxic and must be handled 
under a chemical cabinet. Gloves and lab coat should be worn to avoid 
contact with skin.]. 
4. Wash cells gently three times with DPBS -Ca-Mg. Avoid drying out cells 
between washes. Fixed cultures can be stored at 4 °C for at least 2 weeks 
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before proceeding with the staining. Tightly wrap the plates to avoid 
evaporation of DPBS. 
5. Wash cells gently three times with PBST for 10 min per washing. 
6. Add 250 µL/cm2 of blocking buffer and incubate at room temperature for 20 
min – 1 h. 
7. Without washing, transfer cells to 125 µL/cm2 of primary antibody solution 
(Table 1) in blocking buffer and incubate at room temperature for 2 h with 
gentle rocking. This step can be extended to overnight at 4 °C with gentle 
rocking. 
8. Wash cells gently three times with PBST for 10 min per washing. 
9. Add 125 µL/cm2 of Alexa-Fluor secondary antibody solution (1:200) in 
blocking buffer and incubate at room temperature in the dark for 1 h with 
gentle rocking. 
10. Wash cells gently three times with PBST for 10 min per washing. 
11. Incubate cells in Hoechst solution (1:10,000) in PBST for 5 minutes with 
gentle rocking. 
12. Wash cells gently three times with PBS for 10 min per washing. 
13. Add a drop of Fluorescent mounting medium to a glass microscope slide. To 
avoid air bubbles, touch a coverslip with cells to the mounting medium at an 
angle and slowly lower the coverslip until fully on slide. Mount only a few 
coverslips at a time as the Fluorescent mounting medium dries out fast.  
14. Capture the fluorescence images with a confocal microscope and quantify 
markers by manually counting cells from randomly selected fields. 
 
3.6.2 RNA extraction and qRT-PCR 
Extraction from 1 well of a 12-well plate yields enough RNA for qRT-PCR analyses.  
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1. Wash cells gently once with DPBS -Ca-Mg and discard the liquid. 
2. Add 0.5 mL/well of TRI Reagent® and resuspend the culture by repeatedly 
pipetting up and down [CAUTION: TRI Reagent® is extremely toxic and must 
be handled under a chemical cabinet. Gloves and lab coat should be worn to 
avoid contact with skin.]. 
3. Transfer the resulting lysate into an RNase-free microcentrifuge tube and 
place it on ice. The resulting lysate can be directly processed or stored at -80 
°C for several months. 
4. Perform RNA extraction using TRI Reagent® protocol according to the 
manufacturer’s recommendations. Measure the RNA concentration using the 
Eppendorf BioSpectrometer® basic. The resulting RNA can be directly 
processed or stored at -80 °C for several months. 
5. Synthesise cDNA according to the manufacturer’s recommendations using 
SuperScript® III first-strand synthesis system and random primers. Use the 
same total amount of RNA for each sample. Synthesised cDNA can be 
directly processed or stored at -20 °C until use. 
6. Carry out qRT-PCR according to the manufacturer’s instructions using iQ™ 
SYBR® Green Supermix and a Chromo4 System. Use genes encoding β-
Actin and GAPDH as reference genes and normalise data to the basal 
conditions. The sequence information for all PCR primers used in our initial 
publication is summarised in Table 2. 
 
3.7 Preparation of the Cell Suspension for Transplantation of LGE Progenitors 
into an Animal Model of HD 
1. On D20-22 of differentiation, remove the medium from cultures and gently wash 
cells once with DPBS -Ca-Mg. Aspirate DPBS -Ca-Mg from cells and add 1 
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mL/well for 6-well plates or 0.5 mL/well for 12-well plates of Accutase Cell 
Dissociation Agent. Incubate cultures in dissociation agent for 10 minutes at 37 
°C 5% CO2. Inspect the plates after first 5 minutes and look for floating cells. 
Gently pipette the dissociation agent over the surface of the culture 3 times and 
reject 3 times. Return the plates to 37 °C 5% CO2 for 5 more minutes. 
2. Gently pipette the dissociation agent over the surface of the culture to detach 
and dissociate all cells. Check under a light microscope to confirm that cultures 
are in a quasi-single cell suspension. If not, return the plates to 37 °C 5% CO2 
for 5 more minutes. Do not keep cells in the dissociation reagent for more than 
30 minutes in total, as this decreases cell survival and compromises a 
successful outcome of the experiment. 
3. Collect the cells in the dissociation agent from all wells within the same 
experimental group into a 50 mL centrifuge tube. Set aside a small aliquot of the 
cell suspension to count cells using trypan blue. Add LGE patterning medium to 
the 50 mL tube with the cell suspension at a ratio 4:1 to dilute out the enzymes 
and stop dissociation. Centrifuge at 250 g for 3 minutes. In the meantime, count 
cells in the cell suspension that was set aside. 
4. After centrifugation is completed, aspirate the supernatant from the centrifuge 
tube with a vacuum pump without disturbing the cell pellet. Disrupt the cell pellet 
by gently flicking the tube. Resuspend LGE progenitors in DMEM/F-12 at the 
required concentration (e.g. 1–2.5 x 105 cells/µl) and proceed with the 
transplantation into an animal model of HD. 
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3.8 Cryopreservation of LGE Progenitors 
1. Prior to freezing LGE progenitors, fill the lower chamber of a Mr. FrostyTM 
Freezing Container with isopropanol and pre-chill the container at 4 °C. This 
system is designed to achieve the optimal rate of cooling for cell preservation, 
approximately -1 °C/minute. 
2. On D20-22 of differentiation, LGE progenitors can be frozen either as a single 
cell suspension or as small clusters of cells. To obtain a single cell suspension 
and count cells follow steps in 3.7 and proceed to the next step. To collect LGE 
progenitors in small clusters of cells follow steps in 3.5 and proceed to the next 
step. 
3. Centrifuge at 250 g for 3 minutes. After centrifugation is completed, aspirate the 
supernatant from the centrifuge tube with a vacuum pump without disturbing the 
cell pellet. Disrupt the cell pellet by gently flicking the tube.  
4. Cells can be frozen either in CryoStor® CS10 or in 10% (vol/vol) DMSO solution 
in the LGE patterning medium. If freezing LGE progenitors as a single cell 
suspension, resuspend collected cells in cold cryopreservation medium at the 
concentration of 1–10 x 106 cells/mL. If freezing cultures as small clusters of 
cells, resuspend collected LGE progenitors in cold cryopreservation medium to a 
final volume of 2 mL per well of 6-well plate or 1 mL per well of 12-well plate to 
be frozen. 
5. Add 1 mL of cell suspension to each cryovial and immediately put the vial in the 
freezing container. Transfer the Mr. FrostyTM Freezing Container with cells to a -
80 °C freezer. 
6. On the next day, put cryovials in the short-term storage at -80 °C or long-term 
storage in a liquid nitrogen tank. LGE progenitors can be stored for up to 6 
months at -80 °C and for years in the liquid nitrogen storage tank. 
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3.9 Thawing LGE Progenitors for Downstream Applications 
1. If thawing LGE progenitors for the terminal differentiation into MSNs in vitro, 
prepare the required volume of LGE patterning medium and pre-warm to room 
temperature. The day before thawing cells, start preparing culture vessels or 
glass coverslips coated with PDL/Laminin as described in 3.5. The typical 
density at which LGE progenitors should be seeded is 0.5–1 x 106 cells/cm2 in 1 
mL/well for 12- and 24-well plates. 
2. Pre-warm a water bath to 37 °C. Aliquot 10 mL of LGE patterning medium per 
vial of cells to be thawed into a 15 mL centrifuge tube and warm to 37 °C in a 
water bath. This is the wash media. 
3. Remove cryovials of LGE progenitors from a liquid nitrogen storage bank and 
transfer them on dry ice to a tissue culture room. Thaw frozen vials of cells by 
gently swirling them in the 37 °C water bath until a small pellet of ice remains in 
the cryovial (see Note 10).  
4. Transfer the vials to a laminar flow biosafety cabinet. Using a 2 mL serological 
pipette, quickly but carefully add 1 mL of warm wash medium dropwise to 
thawed cells and transfer the cell suspension to a 15 mL centrifuge tube with the 
remaining wash medium. Using the same pipette, wash the inside of the cryovial 
once with 1 mL of wash medium. Carefully mix the cell suspension in the 15 mL 
tube with a light swirling motion and by gently tapping the tube with a finger. Set 
aside a small aliquot of the cell suspension to evaluate cell viability using trypan 
blue and count cells. 
5. Centrifuge cell suspension in 15 mL tubes at 150 g for 3 minutes. In the 
meantime, particularly if transplanting LGE progenitors, evaluate cell viability and 
count cells in the cell suspension that was set aside in the previous step. If 
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differentiating LGE progenitors into MSNs in vitro, also use this time to transfer 
the culture plates from the incubator to the microbiological safety cabinet. 
6. After centrifugation is completed, aspirate the supernatant from the centrifuge 
tube with a vacuum pump without disturbing the cell pellet. Disrupt the cell pellet 
by gently flicking the tube. 
7. If LGE progenitors are thawed for transplantation into an animal model of HD, 
resuspend cells in DMEM/F-12 at the required concentration (e.g. 1–2.5 x 105 
cells/µl) and proceed with transplantation experiments. If thawed cells are going 
to be differentiated into MSNs in vitro, resuspend cells in the appropriate volume 
of LGE patterning medium to seed 0.5–1 x 106 cells/cm2 in 1 mL/well for 12- and 
24-well plates. 
8. Seed LGE progenitors into the culture container and transfer the plate to a 
humidified 5% CO2 37 °C incubator and ensure cells are distributed evenly 
across wells by gently moving the plate in several quick, short, side-to-side and 
back-and-forth motions. On the next day, proceed to Step 5 in 3.5. 
 
4 Notes 
1. If hPSCs are maintained on feeders, collect hPSCs and pre-plate cultures on 
gelatin for 45 minutes to remove feeder cells before proceeding to seeding cells 
for a differentiation. 
2. We observed a high batch to batch variability with CELLstart when using it as a 
matrix for differentiation. With some batches of CELLstart forebrain progenitors 
detach from the matrix after 9 days in vitro. 
3. The majority of hPSC lines can by maintained in mTeSRTM1 or E8 medium 
culture media on Matrigel matrix or in StemPro medium on Matrigel, CELLstart 
(1:50 in DBPS) or Laminin + Fibronectin matrix (10 µg/mL + 5 µg/mL in DPBS, 
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respectively). However, RC lines (e.g. RC9 and RC17) are best maintained in 
StemPro culture medium on any of the three matrices.  
4. For a successful outcome, hPSC cultures must comprise of homogeneously 
distributed colonies of healthy pluripotent cells, with no contaminating 
differentiated cells. All differentiated colonies should be removed before the start 
of the experiment. When working with a new hPSC line, it is good practice to 
assess cell pluripotency using IF staining or qRT-PCR before the start of the 
neural induction procedure. 
5. CELLstart (1:50 in DBPS) or Laminin + Fibronectin matrices (10 µg/mL + 5 
µg/mL in DPBS, respectively) can also be used at this stage without any effect 
on the efficiency of LGE fate induction. 
6. Do not triturate hPSCs to a single cell suspension, as this severely compromises 
hPSC survival. If the exact number of cells is required for plating, one 70 – 80% 
confluent well of a 6-well plate may be sacrificed and treated with Accutase Cell 
Dissociation Agent for 10 minutes at 37 °C to prepare a single cell suspension 
for cell counting using a vital staining, such as trypan blue. 
7. For a successful neuronal differentiation, seeded cells must be in a monolayer 
with no cell aggregates present. It is equally important that cell colonies are 
evenly distributed across the well to ensure homogeneous cell growth and 
subsequent neural induction. Denser areas of cells will expand quicker and form 
multilayer structures introducing heterogeneity. If cells seeded on GFR Matrigel 
have attached as aggregates, it could be due to (i) too prolonged incubation time 
during coating (do not exceed 1.5 hours) or (ii) coating solution drying out. Use 
sufficient volume of coating solution to avoid it drying out.  
8. While the most convenient stage for this passage is at the end of neural 
induction phase at D9, depending on the speed of neural induction for a given 
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hPSC line/culture, cells may have to passaged before D9. In our hands, 
forebrain progenitors have been successfully transferred to Fibronectin-coated 
culture vessels during D7-12 of differentiation. However, extra care needs to be 
taken to be very gentle with cells if passaging cultures earlier than D9. Although 
patterning of forebrain progenitors towards an LGE fate can be initiated on D9 of 
differentiation, we prefer to delay this by one day if cells are being passaged on 
D9. This allows time for the neural progenitors to recover from passaging and 
avoid potential waste of activin should the progenitors fail to survive and adhere 
well. 
9. Do not incubate forebrain progenitor cultures in EDTA for longer than 2 minutes 
as it would result in too much dissociation and lead to low cell survival after 
passaging. At this stage, neuronal precursors are highly sensitive to the size of 
cell clusters they are passaged in. Do not triturate and dissociate cell suspension 
to small clumps (<300 μm), as this severely compromises forebrain progenitor 
survival. 
10. When thawing cells, do not keep cryovials in the water bath until all ice melts, 
especially if LGE progenitors were frozen in 10% (vol/vol) DMSO solution in the 
LGE patterning medium. Do not allow thawed cells to dwell in the freezing 
medium, as prolonged exposure to DMSO severely affects cell survival. Transfer 
thawed cells to the wash medium as quickly as possible to dilute DMSO. 
Minimise manipulation of the cell suspension with pipettes as newly thawed LGE 
progenitors are delicate. 
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Figure 1. Representative images illustrating the expected cell morphology 
along the protocol. (A) Experimental scheme. (B) Bright field images with phase-
contrast showing characteristic hES H9 cell morphology at different stages along the 
MSN differentiation timeline. Scale bar: 200 µm in B. 
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Figure 2. Efficient generation of medium spiny neurons by activin stimulation. 
Immunostaining for DARPP32 and CTIP2 of D43–45 neurons derived from hES H9 
and RC9 cells in different culture systems. Scale bar: 100 µm for all panels. 
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Figure 3. Generation of striatal projection neurons from cryopreserved LGE 
progenitors. (A) Bright field image with phase-contrast of forebrain progenitors, 
cryopreserved at D9, next day after thawing illustrating very low survival of 
telencephalic precursor cells. (B) Bright field image with phase-contrast of LGE 
progenitors, cryopreserved at D20, next day after thawing showing good survival and 
recovery of neural progenitors with some rosette formation. (C, D) Immunostaining of 
D33 cultures for the indicated markers demonstrating a retained potential of LGE 
progenitors to generate MSNs after cryopreservation process. Scale bars: 200 µm in 
A-C, 50 µm in D. 
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TABLE 1: Antibodies used for immunofluorescence 
Antibody Supplier Cat. No. Dilution 
Anti-Calbindin Swant CB-38a 1:500 
Anti-Ctip2 Abcam 25B6 1:500 
Anti-DARPP32 Santa Cruz Sc-11365 1:200 
Anti-DLX2 Millipore Ab5726 1:300 
Anti-ENK Immunostar 20065 1:400 
Anti-SubP Immunostar 20064 1:400 
Anti-FOXP1 Abcam Ab16645 1:500 
Anti-FOXP2 Abcam Ab58599 1:100 
Anti-FOXG1 Abcam Ab5274 1:250 
Anti-GABA Sigma A2052 1:500 
Anti-GAD65/67 Sigma G5163 1:1000 
Anti-GSX2 Millipore Abn162 1:1000 
Anti-HuNu Millipore Mab1281 1:250 
Anti-hNCAM Santa Cruz Sc-106 1:200 
Anti-MAP2 Sigma M1406 1:250 
Anti-Nestin BD 611659 1:300 
Anti-NeuN Millipore Mab377 1:250 
Anti-NKX2.1 Abcam Ab40880 1:1000 
Anti-NOLZ1 Abnova H00084858-B01F 1:500 
Anti-OTX2 Millipore Ab9566 1:300 
Anti-PAX6 DSHB Ab528427 1:1000 
Anti-PSD95 Thermo Scientific 6G6-1C9 1:200 
Anti-TH Pelfreez P40101 1:500 
Alexa Fluor® Life Technologies Multiple 1:200 
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TABLE 2: List of qPCR primers 
Gene 
Name 
Forward primer sequence Reverse primer sequence 
ARPP21 GGAAGCTGGTTGACGATGTGTC GGCTTCTGTCGTTCTACGCC 
βActin TCACCACCACGGCCGAGCG TCTCCTTCTGCATCCTGTCG 
Calbindin ATCAGGACGGCAATGGATAC TAAGAGCAAGATCCGTTCGG 
CTIP2 CTCCGAGCTCAGGAAAGTGTC TCATCTTTACCTGCAATGTTCTCC 
DARPP3
2 
TTGGAAAATCCAGAAAACCG CTGGTAGAAGCCGGTGAGAG 
DLX2 ACTACCCCTGGTACCACCAGAC TCTGCTCTCAGTCTCTGGCGAGTT
CTC 
DRD2 CTGAGGGCTCCACTAAAGGAG CATTCTTCTCTGGTTTGGCG 
EBF1 AATGTAAGCAAGGTGGACGC TCAAGGTCTAAGCCGGACAC 
FOXG1 TGGCCCATGTCGCCCTTCCT TGGCCCATGTCGCCCTTCCT 
FOXP2 AATGTGGGAGCCATACGAAG GCCTGCCTTATGAGAGTTGC 
GAD67 CGTCTTCGACCCCATCTTCGT CGCAGATCTTGAGCCCCAGTT 
GAPDH ATGACATCAAGAAGGTGGTG CATACCAGGAAATGAGCTTG 
GLI1 TGAGGCCCTTCAAAGCCC GTATGACTTCCGGCACCCTTC 
GSX2 TCACTAGCACGCAACTCCTG TTTTCACCTGCTTCTCCGAC 
NKX2.1 CGCATCCAATCTCAAGGAAT TGTGCCCAGAGTGAAGTTTG 
NOLZ1 ACATTTTGCACCCCGAGTAC GGAGTACGGCTTGAAACTCG 
PAX6 AACAGACACAGCCCTCACAAACA CGGGAACTTGAACTGGAACTGAC 
PENK GCTGTCCAAACCAGAGCTTC TCTGGCTCCATGGGATAAAG 
PTCH1 TTCGCTCTGGAGCAGATTTCCAA
G 
GCTTTTAATCCCACCGCGAAG 
TAC1 TGGGGTTGAAAATTCAAAAAG GGAGTTTCCTTCCTTTTCCG 
TH GAGTACACCGCCGAGGAGATTG GCGGATATACTGGGTGCACTGG 
vGLUT1 AGTTCGCAACGATGATGGCA CTGCACCCCAGCATCTCTGA 
 
